{
    "name": "romosozumab",
    "comment": "Rx",
    "other_names": [
        "Evenity",
        "romosozumab-aqqg"
    ],
    "classes": [
        "Monoclonal Antibodies",
        "Endocrine"
    ],
    "source": "https://reference.medscape.com/drug/evenity-romosozumab-1000158",
    "pregnancy": {
        "common": [
            "Not indicated for use in women of reproductive potential",
            "In animal reproduction studies, weekly administration to pregnant rats during the period of organogenesis at exposures >32 times the clinical exposure produced skeletal abnormalities in the offspring",
            "Administration to rats prior to mating and through to the end of lactation produced minimal-to-slight decreases in femoral bone mineral density and/or cortical circumferences in the offspring at 1.5-56 times the expected exposure in humans"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Not indicated for use in women of reproductive potential"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "May increase the risk of MI, stroke, and CV death",
                "Do not initiate in patients who have had an MI or stroke within the preceding year",
                "Consider whether the benefits outweigh the risks in patients with other CV risk factors",
                "If a patient experiences an MI or stroke during therapy, discontinue drug immediately"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypocalcemia; preexisting hypocalcemia must be corrected before initiating",
                "Systemic hypersensitivity (eg, angioedema, erythema multiforme, urticaria)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "A higher rate of MACE, a composite endpoint of CV death, nonfatal MI, and nonfatal stroke was observed in a randomized controlled trial in postmenopausal women treated with romosozumab compared with alendronate; monitor for signs and symptoms of myocardial infarction and stroke and instruct patients to seek prompt medical attention if symptoms occur",
                "Hypersensitivity reactions reported, including angioedema, erythema multiforme, dermatitis, rash, and urticaria; discontinue drug and initiate appropriate treatment if anaphylaxis or other clinically significant allergic reaction occurs",
                "Hypocalcemia reported; correct hypocalcemia before initiating; monitor for signs and symptoms of hypocalcemia; ensure adequate supplementation with calcium and vitamin D during therapy"
            ],
            "specific": [
                {
                    "type": "Atypical subtrochanteric and diaphyseal femoral fractures",
                    "description": [
                        "Atypical low-energy or low-trauma femoral shaft fractures reported; many patients report prodromal pain in the affected area, usually presenting as dull, aching thigh pain, weeks to months before a complete fracture occurs",
                        "Femoral fractures: During treatment, patients should be advised to report new or unusual thigh, hip, or groin pain; any patient who presents with thigh or groin pain should be suspected of having an atypical fracture and should be evaluated to rule out an incomplete femur fracture",
                        "Patient presenting with an atypical femur fracture should also be assessed for symptoms and signs of fracture in the contralateral limb; interruption of therapy should be considered based on benefit-risk assessment"
                    ]
                },
                {
                    "type": "Osteonecrosis of the jaw",
                    "description": [
                        "ONJ, which can occur spontaneously, is generally associated with tooth extraction and/or local infection with delayed healing and has been reported in patients receiving romosozumab",
                        "Perform routine oral examination before initiating treatment; concomitant administration of drugs associated with ONJ (chemotherapy, bisphosphonates, denosumab, angiogenesis inhibitors, and corticosteroids) may increase ONJ risk",
                        "Other risk factors include cancer, radiotherapy, poor oral hygiene, preexisting dental disease or infection, anemia, and coagulopathy",
                        "For patients requiring invasive dental procedures, clinical judgment of the treating physician and/or oral surgeon should guide the management plan",
                        "Discontinuation should be considered based on benefit-risk assessment"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Study",
            "percent": "1"
        },
        {
            "name": "Myocardial infarction",
            "percent": "0.3"
        },
        {
            "name": "MI",
            "percent": "0.2"
        },
        {
            "name": "placebo",
            "percent": "0.2"
        },
        {
            "name": "Stroke",
            "percent": "0.3"
        },
        {
            "name": "placebo",
            "percent": "0.5"
        },
        {
            "name": "Cardiovascular",
            "percent": "0.4"
        },
        {
            "name": "CV",
            "percent": "0.3"
        },
        {
            "name": "death",
            "percent": "0.2"
        },
        {
            "name": "placebo",
            "percent": "0.2"
        },
        {
            "name": "Myocardial infarction",
            "percent": "0.3"
        },
        {
            "name": "MI",
            "percent": "0.5"
        },
        {
            "name": "placebo",
            "percent": "0.4"
        },
        {
            "name": "Stroke",
            "percent": "2"
        },
        {
            "name": "placebo",
            "percent": "0.8"
        },
        {
            "name": "Cardiovascular",
            "percent": "0.2"
        },
        {
            "name": "CV",
            "percent": "0.6"
        },
        {
            "name": "death",
            "percent": "0.3"
        },
        {
            "name": "placebo",
            "percent": "0.8"
        },
        {
            "name": "Study",
            "percent": "0.6"
        },
        {
            "name": "MI",
            "percent": "2"
        },
        {
            "name": "alendronate",
            "percent": "1.1"
        },
        {
            "name": "Stroke",
            "percent": "1.87"
        },
        {
            "name": "alendronate",
            "percent": "0.8"
        },
        {
            "name": "CV death",
            "percent": "0.2"
        },
        {
            "name": "alendronate",
            "percent": "0.6"
        },
        {
            "name": "Positively adjudicated MACE",
            "percent": "0.3"
        },
        {
            "name": "alendronate",
            "percent": "0.8"
        },
        {
            "name": "hazard ratio",
            "percent": "0.6"
        },
        {
            "name": "MI",
            "percent": "2"
        },
        {
            "name": "alendronate",
            "percent": "1.1"
        },
        {
            "name": "Stroke",
            "percent": "1.87"
        },
        {
            "name": "alendronate",
            "percent": null
        },
        {
            "name": "CV death",
            "percent": null
        },
        {
            "name": "alendronate",
            "percent": null
        },
        {
            "name": "Positively adjudicated MACE",
            "percent": null
        },
        {
            "name": "alendronate",
            "percent": null
        },
        {
            "name": "hazard ratio",
            "percent": null
        }
    ]
}